Osimertinib (Tagrisso; AstraZeneca) is FDA approved for 3 unique cancer indications.
Robert Mownn, PharmD
Advertisement
Articles by Robert Mownn, PharmD
An emerging focus is aligning targeted, safe, and effective therapies with patient goals.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Pharmacy Times
1
Targeting Mitochondrial Metabolism in Heart Failure: From Genetic Drivers to Fuel Modulation Therapies
2
Evolving Mortality Trends in Heart Failure and Vascular Disease: The Critical Role of Pharmacists in Addressing Cardiovascular Risk
3
Sotatercept Demonstrates Significant Reduction in Morbidity and Mortality Across Broader PAH Risk Groups
4
SGLT2 Inhibitors Linked to Lower Atrial Fibrillation Risk, Recurrence
5
